Buckman Co. v. Plaintiffs' Legal Committee
Does federal law preempt state-law tort claims alleging that a company committed fraud on the Food and Drug Administration (FDA) in order to obtain approval of a medical device?
The Decision
9-0 decision · Opinion by William Rehnquist · 2001
Majority Opinion— William Rehnquistconcurring ↓
The Supreme Court reversed the Third Circuit in a unanimous 9–0 decision, holding that the state-law fraud-on-the-FDA claims were impliedly preempted by federal law. Chief Justice William Rehnquist authored the opinion of the Court.
The Court's central reasoning was that so-called 'fraud-on-the-agency' claims are fundamentally different from traditional state tort claims. Unlike ordinary product liability or negligence claims, which exist independently of any federal regulatory scheme, these claims depended entirely on the premise that the FDA had been deceived. The very existence of the plaintiff's cause of action was built on federal law — without the FDA's regulatory framework, there would be no basis for the fraud allegation. The Court described these claims as 'inherently federal in character' because they sought to use state tort law to police the integrity of a federal regulatory process.
The Court emphasized that the FDCA gives the FDA a comprehensive set of tools to deal with fraud, including the authority to withdraw device approvals, issue warning letters, and refer cases for criminal prosecution. Critically, Congress chose not to create a private right of action under the FDCA, signaling that enforcement was meant to rest with the agency, not with private litigants in state court. Allowing state fraud-on-the-FDA claims would effectively add a new layer of punishment and deterrence on top of what Congress designed, upsetting the careful balance struck in the federal statute.
The Court further reasoned that state-law fraud claims would produce problematic incentives for companies seeking FDA approval. If applicants feared that any statement to the FDA could become the basis of a state tort suit, they might either withhold information from the agency or overwhelm it with unnecessary disclosures to protect themselves from liability. Either outcome would impair the FDA's ability to do its job efficiently. The balance between encouraging full disclosure to the agency and punishing fraud was one that Congress assigned to the FDA, not to state courts.
Finally, the Court acknowledged the traditional presumption against preemption in areas of historic state regulation but concluded that this presumption carried less force here. Unlike ordinary health and safety regulation, policing communications between a federal agency and the entities it regulates is not a field in which states have traditionally operated. The claim at issue was not a garden-variety personal injury claim but rather an attempt to enforce what is essentially a federal duty of candor owed to a federal agency.
Concurring Opinions
Justice Stevens filed a concurrence joined by Justice Thomas, cautioning that the Court's opinion should not be read to broadly preempt all state-law claims involving FDA-regulated devices — only the narrow category of 'fraud-on-the-FDA' claims was at issue. Justice Thomas also filed a separate concurrence expressing his broader skepticism about implied 'purposes and objectives' preemption doctrine, though he agreed the claims here were preempted because they existed solely by virtue of the federal regulatory framework.
Background & Facts
This case arose from injuries caused by orthopedic bone screws known as pedicle screws, manufactured by AcroMed Corporation and used in spinal surgery. The Buckman Company was a regulatory consulting firm that AcroMed hired to help navigate the FDA's approval process for these devices. To get the screws onto the market, Buckman used the FDA's '510(k)' process — a streamlined pathway that allows a new device to be cleared for sale if it is shown to be 'substantially equivalent' to a device already on the market. The plaintiffs — patients who were allegedly injured by the screws — claimed that Buckman had made fraudulent misrepresentations to the FDA during this clearance process. Specifically, they argued that Buckman told the FDA the screws would be used for purposes similar to already-approved devices, when in fact they were intended for a different, riskier use in spinal surgery. The theory was that had the FDA known the truth, it would never have cleared the devices, and the plaintiffs would never have been harmed.
The case was consolidated into multidistrict litigation in the Eastern District of Pennsylvania. The district court initially dismissed the fraud-on-the-FDA claims, but the United States Court of Appeals for the Third Circuit reversed, holding that these state-law claims were not preempted by federal law. The Third Circuit concluded that the claims did not directly conflict with the federal regulatory scheme and could coexist with the FDA's own enforcement mechanisms.
The Supreme Court agreed to hear the case because it raised an important question about the boundary between federal regulation of medical devices and state tort law. The Medical Device Amendments of 1976, part of the Federal Food, Drug, and Cosmetic Act (FDCA), gave the FDA comprehensive authority to regulate the safety and marketing of medical devices. Whether state courts could second-guess the FDA's own approval process by entertaining fraud claims against companies that interacted with the agency was a question with significant implications for both the regulatory system and injured patients.
The FDA itself filed an amicus brief urging the Court to find the state-law claims preempted, arguing that private lawsuits policing the integrity of communications between regulated companies and the agency would interfere with its expert regulatory judgment.
The Arguments
Buckman argued that state-law fraud-on-the-FDA claims were preempted by federal law because policing fraud against a federal agency is a uniquely federal function. Allowing state tort suits based on alleged misrepresentations to the FDA would create a second, conflicting layer of enforcement that would undermine the agency's own regulatory authority.
- The relationship between a regulated company and the FDA is inherently federal in nature, and the FDCA gives the FDA specific tools — including the power to withdraw approval and pursue criminal penalties — to address fraud committed against it.
- Allowing fifty different states to create their own standards for what constitutes fraud on the FDA would generate conflicting obligations for companies and deter them from communicating openly with the agency.
- The FDCA does not create a private right of action for violations of FDA regulations, and permitting state fraud-on-the-FDA claims would effectively circumvent that deliberate congressional choice.
The Plaintiffs' Legal Committee argued that their fraud claims were traditional state tort claims that did not conflict with federal law. They contended that states have a longstanding interest in compensating injured residents and that nothing in the FDCA expressly bars state-law fraud claims.
- The state-law claims did not impose any requirements on the device itself that differed from federal requirements — they merely sought to hold Buckman accountable for lying to a federal agency.
- There is a strong presumption against preemption in areas where states have traditionally exercised their police powers, including personal injury litigation.
- The FDA's ability to police fraud on its own does not necessarily mean that state remedies are in conflict with federal law; both enforcement mechanisms can coexist.